Celavie Biosciences

Celavet Animal Health

Celavie Biosciences Team

Sandy Solmon

Sandy Solmon

CEO and President

  • A dynamic entrepreneur recognized for innovation, philanthropy and cutting edge research
  • Founder and CEO, Sweet Street Desserts®, the world’s largest manufacturer of frozen gourmet desserts reaching over 70 countries with more than 700 employees worldwide
  • Awarded 17 US copyrights for the design of food products
  • Honors include:
    • Honorary Doctorate, Alvernia University
    • 2014 Cornell University Hospitality Innovator Award
    • Culinology Top Innovation Award by Research Chef’s Association
    • Pennsylvania’s Best 50 Women in Business Award
  • Lead venture investor, Celavie Biosciences LLC
Oleg Kopyov, MD, PhD

Oleg Kopyov, MD, PhD

Executive Vice President and Chief Scientific Officer

  • Instrumental in the research and development of neurosurgical treatments for brain diseases
  • Special interests include pathology, cerebellar ataxia, epilepsy, and stroke
  • Director of Research, California Neuroscience Institute, St. John’s Regional Medical Center, Los Angeles
  • Director of Clinical Research, The Neuroscience Institute, Good Samaritan Hospital, Los Angeles
  • Head, Department of Experimental Neurosurgery, Kiev Research Institute of Neurosurgery, Ukraine
  • Doctor of Medical Sciences degree, Kiev Research Institute of Neurosurgery, 1985
  • PhD in Neurophysiology and Neuroanatomy, Kiev Research Institute of Neurosurgery, 1973
  • Medical Doctor degree, Kiev Medical Institute, 1969
  • Research projects include:
    • Animal and clinical experimentation aimed at developing new neurosurgical treatments for Parkinson’s, Huntington’s, and Alzheimer’s diseases, epilepsy, and spinal cord trauma
    • Employing deep brain stimulation (DBS) and stem cell technology for brain repair
  • Pioneered fetal tissue transplant for Parkinson’s disease in the early 1990s
  • Published over 150 articles and monographs
Ignacio Madrazo Navarro, MD, MSc, PhD, FACS, FAANS

Ignacio Madrazo Navarro, MD, MSc, PhD, FACS, FAANS

Principal Investigator, Phase I Trial

  • Over 54 years of experience as a neurosurgeon, professor, and researcher
  • Neurosurgeon, Hospital Angeles Pedregal, Mexico City
  • Performed first experimental transplantation of nerve cells taken from a human embryo
  • Specializes in the treatment of Parkinson’s and Huntington’s diseases
  • Current research includes central nervous system (CNS) regeneration mechanisms of the spinal cord
  • Pioneer in the area of brain transplants
  • Head, National Investigation, National Medical Center La Raza, Mexican Social Security Institute (IMSS)
  • Researcher, Level lll, National System of Researchers
  • Member, Advisory Council of Sciences of the Presidency of the Republic, Mexico
  • PhD, Medical Sciences, Universidad Nacional Autónoma de México, Mexico City
  • In 2012, recognized for his work for the treatment of Parkinson’s by the National Academy of Medicine, Mexico
  • Published over 200 articles for international magazines and 4 books
Christopher Duma, MD, FACS

Christopher Duma, MD, FACS

Principal Investigator, Phase II Trial and Clinical Advisor

  • Over 30 years experience as a board-certified neurosurgeon with specialties in surgical brain tumor management, Gamma Knife and CyberKnife™ radiosurgery, and the surgical treatment of movement disorders
  • Medical Director, Hoag/UCI Gamma Knife Program, Hoag Memorial Hospital Presbyterian, Newport Beach, CA
  • Assistant Clinical Professor, School of Medicine, Department of Neurosurgery, University of California, Irvine
  • Head, Division of Radiosurgery, UC Irvine, School of Medicine, Department of Neurosurgery
  • Vice-Chairman, Department of Neurosurgery, Hoag Memorial Hospital Presbyterian
  • Member, International Stereotactic Radiosurgery Society
  • Member, Congress of Neurological Surgeons
  • Member, American Association of Neurological Surgeons
Raymond J. Hage, Jr.

Raymond J. Hage, Jr.

Strategic Advisor

  • Over 25 years of leadership in pharmaceuticals, biologics and consulting – sales, marketing, new product planning, business development, regulatory, intellectual property, manufacturing and early-stage development
  • Founder, President, CEO, and Board Member, Hapten Sciences, Inc., identifying and developing novel, early-stage products that will contribute to the well-being of people around the world
  • Chief Operating Officer and Senior Vice President of Commercial Operations, Novavax
  • Over 11 years with Eli Lilly, including Sales, Sales Management, Marketing, Pricing, Market Research, Strategic Planning, and Director of US Women’s Health
  • Founder and President, Focal Point Pharmaceuticals, Inc. (eye diseases, US Army Grant)
  • Executive Program, University of Michigan
  • MBA Finance and Marketing, Fisher School of Business, The Ohio State University
  • BS in Business and Economics with honors, University of Kentucky
Clemente Associates, Ltd

Clemente Associates, Ltd

Medical and Regulatory Advisor

  • Over 25 years across disciplines in the pharmaceutical industry
  • Chief Medical Officer, Clementi Associates
  • Academic appointment in the School of Medicine and in the College of Pharmacy, the University of Texas Health Science Center, San Antonio
  • Held executive positions at Wyeth, including Vice President of New Products Marketing and VP Global Medical Communications within Global Medical Affairs
  • Early industry career at E.R. Squibb & Sons, G.D. Searle and Eastman Kodak/Sterling Drug/Sanofi Winthrop in clinical research, regulatory affairs and strategic planning/portfolio management
  • Experienced with promotional review and compliance, MSL strategies and issues, medical information/call centers, clinical research – all phases, medical marketing and product crafting/positioning, insourcing/off-shoring strategy development and management
  • Board Certified, American Board of Internal Medicine
James Robinson

James Robinson

Manufacturing and Regulatory Advisor

  • Over 30 years experience in pharmaceutical manufacturing, process development, and quality operations
  • Vice President, Technical Operations, Vaccines, Biologics and Sterile Manufacturing, Merck & Co.
  • Vice President, Technical and Quality Operations, Novavax, responsible for developing recombinant virus-like particle vaccine for influenza, RSV and other targets
  • Over 20 years in executive management at sanofi pasteur in production, development and engineering; most recently as Vice President, Industrial Operations; executive responsible for US vaccine supply
  • Industrializing vaccine and therapeutic protein manufacturing technologies, by managing the production of over 2 billion doses of nearly every approved vaccine, including influenza, tetanus, meningitis, chicken pox, shingles, rotavirus, MMR, HPV, hepatitis A&B, and development of recombinant protein vaccines
  • Editorial Advisory Board Member and featured in Life Science Leader Magazine in 2012 for transforming Merck’s approach to vaccine manufacture
Howard Schwartz

Howard Schwartz

Legal Advisor – DLA Piper® USA LLP

  • Structures and negotiates mergers and acquisitions, complex collaborations, joint ventures, and financings for multinational bio-pharmaceutical and device companies, as well as emerging-growth and other successful businesses
  • Advises boards of directors and significant shareholders on disclosure issues, corporate communications policies and fiduciary duty matters
  • Represents life sciences clients in their operational matters, such as supply, distribution, clinical trials, manufacturing and research and license arrangements between industry and academic institutions
  • Clients extend throughout the US, Europe and Asia as well as to emerging markets
  • Deal experience includes all segments of the technology and IP-driven industries—pharma, biotech, medtech, diagnostics, animal health, vaccines, and health services—for aspects of business structures, including franchise, joint venture and acquisition
  • For over 20 years has focused on meeting the specialized corporate, commercial and transactional needs of growing companies
  • Former Co-Chair, DLA Piper’s Life Sciences practice group
  • Recognized as a leading practitioner in his field by peers, including in the 2016 edition of The Best Lawyers in America for the practice area of biotechnology

Contact Celavie Biosciences

Changing the Paradigm of Regenerative Medicine and Stem Cell Technology